Institute News
Most Popular
Phase 3 Trial Currently Enrolling MacTel Patients
In a collaboration with Neurotech Pharmaceuticals, the Lowy Medical Research Institute is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2. This is a multi-center...
The Latest MacTel Research: What does it mean for patients?
Scientists at the Lowy Medical Research Institute and their collaborators recently published an article describing a role for serine and toxic lipids in macular telangiectasia type 2. The article, “Serine and Lipid Metabolism in Macular Disease and...
Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia
Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), today announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macul...
Results of NT-501 Phase 2 Study Published
January 16, 2019, Cumberland, RI and La Jolla, CA. The results of the NT-501 Phase 2 study sponsored by Neurotech Pharmaceuticals, Inc. (Neurotech) in collaboration with the Lowy Medical Research Institute (LMRI), have been published in the journal o...